/
Other
GIST
6
Pipeline Programs↗
14
Active Trials↗
23
Companies Involved↗
GIST is an early-stage landscape with 6 programs across 23 companies. The most active players are Deciphera Pharmaceuticals, LLC, Taiho Pharmaceutical Co., Ltd.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 21
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
5 of 6 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.
Analysis
Trial Status
71
clinical trials
Completed33 · 46%
Unknown status16 · 23%
Recruiting9 · 13%
Terminated6 · 8%
Active, not recruiting3 · 4%
Not yet recruiting2 · 3%
Other2 · 3%
Clinical Trials
Trial Activity
71 trials
Cognitive Neurology Unit Clinical Registry
Recruiting·—·N/A·NCT05925621·500 enrolled
University of Iowa Interventional Psychiatry Service Patient Registry
Recruiting·—·N/A·NCT04480918·1,000 enrolled
PH 2 Pemigatinib in SDH-deficient GIST
Not yet recruiting·—·Phase 2·NCT07434843·24 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)